Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies

Cancer Science

Volumn 101, Issue 3, 2010, Pages 594-600

  Tanaka Harada, Yukie ^a   Kawakami, Manabu ^a   Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Katagiri, Takamasa ^a   Olga, Elisseeva ^a   Nishida, Sumiyuki ^a   Shirakata, Toshiaki ^a   Hosen, Naoki ^a   Fujiki, Fumihiro ^a   Murao, Ayako ^a   Nakajima, Hiroko ^a   Oji, Yusuke ^a   Kanda, Yoshinobu ^b   Kawase, Ichiro ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; T LYMPHOCYTE RECEPTOR BETA CHAIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DENATURATION; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LYMPHOCYTE DIFFERENTIATION; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, T-CELL RECEPTOR BETA; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CCR7; WT1 PROTEINS;

EID: 77949640425     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01453.x     Document Type: Article

References (39)

1. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992, 257:674-8.
2. Englert C, Hou X, Maheswaran S. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995, 14:4662-75.
3. Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 1995, 10:1125-9.
4. Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995, 55:5386-9.
5. Inoue K, Sugiyama H, Ogawa H. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994, 84:3071-9.
6. Tamaki H, Ogawa H, Ohyashiki K. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999, 13:393-9.
7. Oji Y, Ogawa H, Tamaki H. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999, 90:194-204.
8. Oka Y, Udaka K, Tsuboi A. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000, 164:1873-80.
9. Tsuboi A, Oka Y, Ogawa H. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000, 20:195-202.
10. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95:286-93.
11. Gao L, Bellantuono I, Elsasser A. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95:2198-203.
12. Tsuboi A, Oka Y, Udaka K. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002, 51:614-20.
13. Elisseeva OA, Oka Y, Tsuboi A. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99:3272-9.
14. Wu F, Oka Y, Tsuboi A. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 2005, 19:268-74.
15. Oka Y, Tsuboi A, Taguchi T. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004, 101:13885-90.
16. Kawakami M, Oka Y, Tsuboi A. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007, 85:426-9.
17. Valmori D, Dutoit V, Lienard D. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8 + T cells in melanoma patients. J Immunol 2000, 165:533-8.
18. Willhauck M, Mohler T, Scheibenbogen C. T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res 1996, 2:767-72.
19. Pilch H, Hohn H, Freitag K. Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis. Clin Diagn Lab Immunol 2002, 9:257-66.
20. Sensi M, Salvi S, Castelli C. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 1993, 178:1231-46.
21. Dietrich PY, Walker PR, Quiquerez AL. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res 2001, 61:2047-54.
22. Valmori D, Dutoit V, Schnuriger V. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002, 168:4231-40.
23. Salvi S, Segalla F, Rao S. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 1995, 55:3374-9.
24. Ostankovitch M, Le Gal FA, Connan F, Chassin D, Choppin J, Guillet JG. Generation of Melan-A/MART-1-specific CD8 + cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. Int J Cancer 1997, 72:987-94.
25. Romero P, Gervois N, Schneider J. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997, 159:2366-74.
26. Mandruzzato S, Rossi E, Bernardi F. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 2002, 169:4017-24.
27. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol 2004, 173:7622-9.
28. Price DA, Brenchley JM, Ruff LE. Avidity for antigen shapes clonal dominance in CD8 + T cell populations specific for persistent DNA viruses. J Exp Med 2005, 202:1349-61.
29. Kalams SA, Johnson RP, Trocha AK. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J Exp Med 1994, 179:1261-71.
30. Roers A, Montesinos-Rongen M, Hansmann ML, Rajewsky K, Kuppers R. Amplification of TCRbeta gene rearrangements from micromanipulated single cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin's disease are polyclonal. Eur J Immunol 1998, 28:2424-31.
31. Champagne P, Ogg GS, King AS. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106-11.
32. Polz MF, Cavanaugh CM. Bias in template-to-product ratios in multitemplate PCR. Appl Environ Microbiol 1998, 64:3724-30.
33. Akolkar PN, Gulwani-Akolkar B, Pergolizzi R, Bigler RD, Silver J. Influence of HLA genes on T cell receptor V segment frequencies and expression levels in peripheral blood lymphocytes. J Immunol 1993, 150:2761-73.
34. Burrows SR, Silins SL, Cross SM. Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. Eur J Immunol 1997, 27:178-82.
35. Geursen A, Skinner MA, Townsend LA. Population study of T cell receptor V beta gene usage in peripheral blood lymphocytes: differences in ethnic groups. Clin Exp Immunol 1993, 94:201-7.
36. Kasprowicz V, Isa A, Jeffery K. A highly restricted T-cell receptor dominates the CD8 + T-cell response to parvovirus B19 infection in HLA-A*2402-positive individuals. J Virol 2006, 80:6697-701.
37. Kumamaru W, Nakamura S, Kadena T. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma. Int J Cancer 2004, 108:686-95.
38. Shimizu K, Yamaguchi Y, Ohta K, Miyahara E, Toge T. Analysis of T cell receptors reactive with squamous cell carcinoma antigen SART-1 presented by the HLA-A24 molecule. Oncol Rep 2002, 9:599-605.
39. Gomi S, Nakao M, Niiya F. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999, 163:4994-5004.